Developing treatment strategies for triple-negative breast cancer (TNBC) has become an important clinical challenge. Currently, taxane-based chemotherapy is one of the standard treatments for TNBC. However, determining the key factor of taxane-resistance is urgently in need for clinical treatment for breast cancer. We used GEO data to generate paclitaxel resistance in two basal-like TNBC cell lines (SUM149 and MDA-MB-468). Seventy-one common upregulated differentially expressed genes (DEGs) and 11 downregulated DEGs were found to be related to paclitaxel resistance. By constructing protein-protein interactions, 28 hub proteins with a degree cutoff criterion of â„1 were found. Nine hub genes (
COL4A6
,
COL4A5
,
IL6
,
PDGFA
,
LPAR1
,
FYB
,
IL20
,
IL18R1
and
INHBA
) are involved in important signaling pathways
.
We found that upregulated
PDGFA
and downregulated
COL4A6
were significantly associated with an insensitive response to neoadjuvant paclitaxel-based therapy. A Kaplan-Meier plot was created to check the prognostic values of 11 hub DEGs in terms of recurrence-free survival. High expressions of
PDGFA
and
LAMB3
were correlated with poor recurrence-free survival, while low levels of
FYB
,
IL18R1
, and
RASGRP1
indicated poorer relapse-free survival. Our results suggest that
PDGFA
,
COL4A6
,
LPAR1
,
FYB
,
COL4A5
, and
RASGRP1
might be candidate target genes for taxane-based therapy in basal-like TNBC.